Drug Type CRISPR/Cas9 |
Synonyms- |
Target |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Scribe TherapeuticsStartup |
Active Organization Scribe TherapeuticsStartup |
Inactive Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiovascular Diseases | Discovery | - | Scribe TherapeuticsStartup | 09 Jun 2022 |
end organ damage | Discovery | - | Scribe TherapeuticsStartup | 09 Jun 2022 |
Functional disorder | Discovery | - | Scribe TherapeuticsStartup | 09 Jun 2022 |
Hematologic Diseases | Discovery | - | Scribe TherapeuticsStartup | 09 Jun 2022 |
Hypoxia | Discovery | - | Scribe TherapeuticsStartup | 09 Jun 2022 |
Nervous System Diseases | Discovery | - | Scribe TherapeuticsStartup | 09 Jun 2022 |
Urogenital Diseases | Discovery | - | Scribe TherapeuticsStartup | 09 Jun 2022 |